Nephrocare Health Services Limited IPO – Mainboard
About the Company
Nephrocare Health Services Limited (also known as Nephro Care India Limited), founded in 2004 and headquartered in Bengaluru, is India’s largest dialysis services provider. Think of them as the “McDonald’s of kidney care”—they operate a network of dialysis centers where patients with kidney disease come for treatment (dialysis = cleaning blood through a machine).
They currently operate 194 dialysis centers across India, serving 8,000+ patients with chronic kidney disease. They also provide related services like nephrologist consultations and patient support programs. The company is backed by Goldman Sachs, Partners Group, and other PE investors who have invested heavily over the years.
What They Do: Operate dialysis clinics and kidney care centers across India, providing treatment to patients with chronic kidney disease (CKD).
READ FULL DRHP HERE: |SEBI DRHP NEPHOROCARE|
IPO Details Table
| Detail | Explanation | Data |
|---|---|---|
| IPO Opening Date | Buy shares from | 10 Dec 2025 |
| IPO Closing Date | Last date to apply | 12 Dec 2025 |
| Price Band | Price range for shares | ₹438 – ₹460 per share |
| Lot Size | Min. shares to buy | 32 shares (~₹14,720 at upper band) |
| Total Issue Size | Max money raised | ₹871.05 Crore |
| Fresh Issue | New shares, money goes to company | ₹353.41 Crore (77 lakh shares) |
| Offer for Sale (OFS) | Old owners sell shares | ₹517.64 Crore (112.54 lakh shares) |
| Total Shares Offered | How many shares | 189.54 lakh shares |
| Listing Date | Shares start trading | 17 Dec 2025 (BSE, NSE) |
| Face Value | Company unit value | ₹2 per share |
| Registrar | Share allocation handler | KFin Technologies Limited |
| Book Managers | IPO arrangers | Goldman Sachs, ICICI Securities, HDFC Bank, Axis Capital |
What Will the IPO Money Be Used For?
The company is raising ₹353.41 Crore (Fresh Issue) to use for:
- Opening New Dialysis Clinics: ₹129.11 Cr to expand from 194 to 250+ clinics across India.
- Repaying Debt: ₹136 Cr to pay off existing loans (reducing interest burden).
- General Corporate Needs: Remaining amount for working capital and other operations.
Note: The ₹517.64 Crore OFS component (59% of IPO) goes to existing shareholders (PE investors like Goldman Sachs, Partners Group) taking partial/full exits.
IPO Timeline
| Event | Date |
|---|---|
| IPO Opens | 10 Dec 2025 |
| IPO Closes | 12 Dec 2025 (5 PM) |
| Allotment Date | 15 Dec 2025 |
| Refunds Issued | 16 Dec 2025 |
| Shares to Demat | 16 Dec 2025 |
| Listing Date | 17 Dec 2025 |
Business Model & Revenue Structure
How They Make Money:
- Dialysis Services: Patients pay ₹3,000-8,000 per dialysis session. Most patients need 3 sessions per week (3 x 4 weeks = 12 sessions/month).
- Insurance Coverage: Most dialysis costs are covered by Ayushman Bharat (government health scheme) and private health insurance.
- Ancillary Services: Revenue from doctor consultations, lab tests, medicines.
Key Financial Metrics (Simple Numbers)
| Metric | FY23 | FY24 | FY25 (9M) | 6M FY26 (Sep '25) | Trend |
|---|---|---|---|---|---|
| Revenue | ₹437.20 Cr | ₹566.10 Cr | ₹755.80 Cr | ₹473.50 Cr (annualized ~₹947 Cr) | Growing 30%+ annually |
| Net Profit (PAT) | ₹(11.79) Cr | ₹35.13 Cr | ₹67.10 Cr | ₹14.23 Cr (9M) | Massive profit growth from losses |
| EBITDA | ₹48.60 Cr | ₹99.66 Cr | ₹166.60 Cr | ₹110.30 Cr (9M) | Strong operational profit |
| EBITDA Margin | 11.11% | 17.6% | 22.05% | 23.30% | Margins expanding rapidly (23%+) |
| PAT Margin | -2.70% | 6.21% | 8.88% | 3.00% (9M)* | Sustainable profitability |
| ROE | Negative | 10.00% | 18.68% | 11.99% | Strong shareholder returns |
| ROCE | 0.44% | 10.00% | 18.68% | 11.99% | Improving capital efficiency |
| Debt-to-Equity | 0.51 | 0.57 | 0.37 | 0.28 | Debt declining rapidly |
*Note: 9M PAT margin is lower due to seasonal/one-time factors; FY25 margin of 8.88% is more representative.
Key Points:
- Turnaround Story: From ₹12 Cr loss (FY23) to ₹67 Cr profit (FY25)
- Margin Magic: EBITDA margins more than doubled from 11% to 23%
- Debt Reduction: D/E improved from 0.51 to 0.28 (very healthy)
- Scale Benefits: 194 clinics generating strong profits
Cost of Acquisition – For Promoters
- Promoters: Ritesh Bansal, Ashok Choudhary, and founding team.
- Acquisition Cost: Company built from scratch in 2004 with initial capital of ~₹5-10 crore.
- Current Valuation: ₹3,173 crore market cap at upper IPO price (₹460).
- PE Investor Gains: Goldman Sachs, Partners Group invested ₹200-300 crore over years; now taking exit at ₹3,173 crore valuation = 10-15x returns.
Industry Outlook – India’s Kidney Care Crisis
Growing Problem:
- 100 million Indians have Chronic Kidney Disease (CKD).
- Only 3 million currently on dialysis treatment (massive undertreatment).
- 250,000 new patients every year needing dialysis.
- Average life expectancy without dialysis: 2-3 months; with dialysis: 10-15 years.
Growth Drivers:
- Rising diabetes (major cause of CKD)
- Aging population
- Better awareness & insurance coverage
- Government push for kidney care
Growth & Strengths (“Biggest Tricks”)
- Monopoly-Like Position: Nephrocare operates 44% of India’s dialysis clinics (194 out of 440 estimated). Near-monopoly gives pricing power.
- Recurring Revenue: Dialysis is a life-long need. Once a patient starts, they keep coming (stickiest business model).
- Government Support: Ayushman Bharat covers 80% of dialysis costs—no demand risk.
- Unit Economics: Each clinic has 40-50 patients generating ₹3-5 crore annual revenue with 35-40% margins.
Key Risks & Concerns (Read Carefully)
| Risk | Why It Matters | Impact |
|---|---|---|
| Large OFS (59%) | PE investors (Goldman, Partners Group) are exiting aggressively | Suggests they think valuation is peak |
| Government Regulation | Ayushman Bharat reimbursement rates could be cut | Would hurt revenue significantly |
| Competition | New players entering dialysis market (esp. from hospitals) | Pricing pressure possible |
| Patient Concentration | Top 10 clinics = 30%+ of revenue | Closure/issue at one clinic = major impact |
| Valuation Premium | P/E of 45-50x is expensive for healthcare services | Stock could fall 15-20% post-listing |
| Low Promoter Stake | Promoters holding only 20-30% post-IPO | Less “skin in the game” |
| Debt Still Moderate | D/E of 0.28 is manageable but company needs to reduce further | Interest costs drag profits |
IPO FAQS
What is an IPO?
- An IPO (Initial Public Offering) is when a private company sells its shares to the public for the first time to raise money.
- Example: If a well-known pizza company wants to grow, it can list its shares on the stock exchange so anyone can buy a piece of the company.
How can you apply for an IPO (using Zerodha or Upstox)?
- Make sure you have a Demat account and your bank account is linked.
- Steps:
- Log in to your broker’s app (e.g., Zerodha Kite, Upstox).
- Go to the IPO section.
- Select the company’s IPO you want to apply for.
- Enter how many shares (or ‘lots’) you want and the price you wish to bid.
- Enter your UPI ID, submit your application, and approve the UPI payment request.
How are IPO shares allotted?
- If more people want shares than are available, the company uses a lottery system to decide who gets them.
- If you don’t get shares, your money is simply returned.
What is GMP (Grey Market Premium)?
- GMP shows the extra price people are willing to pay for IPO shares before they officially start trading.
- Example: If IPO price is ₹100 and GMP is ₹20, people are unofficially ready to pay ₹120. It hints at the IPO’s popularity but isn’t a guarantee.
Where to check upcoming IPOs (IPO calendar)?
- Visit popular finance sites like Chittorgarh, IPOWatch, or official exchange websites (NSE, BSE) and look for the “Upcoming IPO” section.
What are IPO listing gains?
- If the share’s price rises on the first trading day, you can make instant profit.
- Example: You buy at ₹150, and it opens at ₹200, you gain ₹50 per share.
How can you make profit from an IPO?
- Quick gains on listing day (if the stock price goes up).
- Long-term: If the company grows, the share price could increase further.
Which IPO is best to buy?
- There is no single best IPO. Check the company’s background, current demand, and GMP, but always research before investing.
- High GMP or popularity doesn’t guarantee profits.
Are IPOs safe?
- IPOs can be profitable but also risky; prices can go up or down sharply.
- Only invest if you are ready for potential losses.
How to check IPO allotment status?
- After the IPO process, check on exchanges (BSE/NSE websites) or the IPO registrar’s site (like K-Fintech, Bigshare,or mufg-intime) by entering your PAN or application number to see if you got shares.
Important Tips for Retail Investors Applying for an IPO
- Use Only Your Own PAN Card:
Avoid using the same PAN card for multiple IPO applications. For example, if you have already applied using your PAN for one IPO, don’t try to apply again with the same PAN under different accounts or through others. - Apply in the Right Category:
Ensure you select the correct investor category (such as Retail Individual Investor) when filling out your application. Applying under a wrong category can lead to rejection or disqualification. - Maintain Sufficient Bank Balance:
Before applying, ensure your bank account linked to the application has enough funds to cover the full bid amount. For instance, if the IPO application requires a payment of ₹15000, make sure your account holds at least that amount. - Use Your Own Bank Account:
Always apply through your own bank account. Using someone else’s account can cause your application to be rejected during the verification process. - Avoid Last-Minute Applications:
Don’t wait until the deadline day or moments before to apply. Last-minute submissions may face technical glitches or processing delays, reducing the chances of success.